Key Highlights

  • Repligen (NASDAQ:RGEN) reports third-quarter results before the open on Tuesday, October 27, 2026, with consensus adjusted earnings of USD 0.46 per share, below the USD 0.54 delivered in the second quarter.
  • Second-quarter revenue was USD 204.1 million, up 12% reported and 13% organic, and management raised 2026 organic growth guidance to 10.5% to 13.5% and adjusted earnings to USD 2.03 to USD 2.09.
  • Adjusted gross margin was 53.9% and the adjusted EBITDA margin 21.4% in the second quarter, so margin delivery is the second test after revenue growth.
  • Results cannot be known in advance, and the pending BioLife Solutions acquisition is excluded from guidance, which keeps deal commentary in focus.

Repligen (NASDAQ:RGEN) Setup: Consensus Against the July Raise

Repligen (NASDAQ:RGEN) supplies filtration, chromatography and analytics products used to make biological medicines, and it reports third-quarter results before the open on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 0.46 per share. In the company's release of Tuesday, July 28, 2026, second-quarter revenue was USD 204.1 million against USD 182.4 million a year earlier, and adjusted earnings were USD 0.54 against USD 0.37. Management described sequential acceleration and said order momentum from the first quarter had continued, with improved visibility into the second half. Full-year revenue guidance is USD 813 million to USD 835 million, and the company held USD 810 million of cash and marketable securities at June 30, 2026.

Why Orders and Margins Drive Repligen (NASDAQ:RGEN)

Bioprocessing suppliers sell consumables that customers reorder as drug production runs, so revenue follows customer batch activity and the destocking cycle that followed the pandemic. Repligen (NASDAQ:RGEN) guided to a gross margin of 53.7% to 54.2% and an adjusted EBITDA margin of 20.6% to 21.0% for 2026. The first half produced revenue of USD 398.4 million, so by simple arithmetic the second half implies USD 414.6 million to USD 436.6 million, which is the range consensus must sit within. Guidance excludes the pending acquisition of BioLife Solutions (NASDAQ:BLFS), a cell and gene therapy supplier, and includes a headwind of about one point from the Polymem divestiture. Peers reporting this season give read-across on customer demand.

Risks and What to Watch

The bull case is adjusted earnings above USD 0.46, organic growth near or above the top of the guided range and margins held near the second-quarter levels. That would confirm the recovery in orders, and the shares could rise. The bear case is a miss, a slowdown in orders that makes the second-half implied revenue look demanding, or a cautious tone on the BioLife integration and funding, which could lead to a sharp fall given the valuation attached to growth. Investors should watch order trends by customer type, the gross margin, the tariff and cost commentary and the timetable for closing the acquisition. The Federal Reserve decides on Wednesday, October 28, 2026, after raising rates on Wednesday, September 16, 2026, which bears on growth stock valuations.

Where Things Stand

The answer is that Repligen (NASDAQ:RGEN) must show that the July raise was sound, so a beat against USD 0.46 per share is expected and the second-half outlook matters more. The company needs organic growth inside 10.5% to 13.5% and margins near guidance. The next catalysts are the release before the open on Tuesday, October 27, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026. Estimates and guidance are not guarantees, and this is not investment advice.